The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
 
Charles S. Fuchs
Leadership - CytomX Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; Entrinsic Health; EvolveImmune Therapeutics
Consulting or Advisory Role - Agios; Amylin; Bain Capital; CytomX Therapeutics; Daiichi Sankyo; Entrinsic Health; EvolveImmune Therapeutics; Genentech/Roche; Lilly; Merck; Sanofi; Taiho Pharmaceutical; Unum Therapeutics
Expert Testimony - Amylin; Lilly
 
Mustafa Özgüroğlu
Travel, Accommodations, Expenses - AstraZeneca
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; GlaxoSmithKline; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Maria Di Bartolomeo
Honoraria - Lilly; MSD Oncology; SERVIER
Consulting or Advisory Role - Lilly; MSD Oncology
Research Funding - Lilly
Travel, Accommodations, Expenses - Roche; Sanofi
 
Mario Mandalà
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
 
Min-hee Ryu
No Relationships to Disclose
 
Lorenzo Fornaro
Honoraria - Lilly
Consulting or Advisory Role - MSD
Research Funding - Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Celgene
 
Tomasz Olesinski
No Relationships to Disclose
 
Christian Caglevic
Consulting or Advisory Role - Andes Biotechnologies; boehringer ingelheim; Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - Bristol-Myers Squibb; Lilly; MSD; Roche
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Medivation; Merck Sharp & Dohme; Roche
 
Hyun Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Anneli Elme
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Amgen; MSD; Roche
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Roche; SERVIER
Research Funding - Merck Serono
 
Ian Chau
Honoraria - Lilly
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Oncologie; Pierre Fabre; Roche/Genentech
Research Funding - Janssen-Cilag (Inst); Lilly (Inst); Merck Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Chugai Pharma; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb
 
Pooja Bhagia
No Relationships to Disclose
 
Anran Wang
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Chie-Schin Shih
Employment - Merck
Research Funding - Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)